Drugs / ITI-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05698199 | Aug 2023 → Feb 2026 | glioblastoma | Immunomic Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITI-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05698199 ↗ |
| Modality | Vaccine | “ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens.” NCT05698199 ↗ |
| Route | Intramuscular | “8mg of ITI-1001 DNA vaccine will be administered via IM injection with electroporation up to 9 times using the TDS-IM v2.0 Device” NCT05698199 ↗ |